← back to search

Jinjun Ye

Guangzhou University of Chinese Medicine · CN
Area of research
Surgery · Oncology
Research interest
Research interests include Medicine, Esophageal squamous cell carcinoma, Chemoradiotherapy, Oncology, Cancer research, and Chemotherapy.
h-index
citations
199
works
9
NIH funding
primary concept
email

Recent publications

Tripartite motif-containing protein 28 promotes drug resistance to bortezomib in gastric cancer through proteasome activity regulation
CytoJournal 2026cited by 0position: lastdoi
Metal Ion-Based Chemical Coordination Amplification: A Chromophore In Situ Deposition Strategy for Visual Sensitivity-Enhanced Lateral Flow Immunochromatography Assays
Analytical Chemistry 2025cited by 16position: middledoi
Cold Exposure Therapy Enhances Single-Atom Nanozyme-Mediated Cancer Vaccine Therapy
ACS Applied Materials & Interfaces 2025cited by 5position: firstdoi
ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCC
Future Oncology 2025cited by 3position: middledoi
The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local primary-recurrence esophageal squamous cell carcinoma after definitive chemoradiotherapy: A prospective, multicenter, single-arm clinical study (ESO-Nanjing12).
Journal of Clinical Oncology 2025cited by 0position: lastdoi
Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study
Cancer Immunology Immunotherapy 2025cited by 0position: middledoi
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial
EClinicalMedicine 2024cited by 31position: middledoi
Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study
Therapeutic Advances in Medical Oncology 2024cited by 3position: middledoi
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial
˜The œLancet. Gastroenterology & hepatology 2023cited by 72position: middledoi
Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer
JAMA Network Open 2022cited by 72position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Kuaile Zhao · Shanghai Medical College of Fudan University5 papers (2022–2025)Dashan Ai · Shanghai Medical College of Fudan University3 papers (2022–2024)Guoren Zhou · Sun Yat-sen University Cancer Center3 papers (2022–2025)Wenbin Shen · Henan Institute of Technology3 papers (2024–2025)Junqiang Chen · Shandong University3 papers (2023–2025)Dayong Gu · Shantou University3 papers (2022–2025)Hong Ge · Chinese Academy of Medical Sciences & Peking Union Medical College2 papers (2024–2025)Yuanji Xu · Guangzhou University of Chinese Medicine2 papers (2024–2025)Wenyang Liu · University of Shanghai for Science and Technology2 papers (2024–2025)Shihong Wei · Sun Yat-sen University Cancer Center2 papers (2022–2023)Shengnan Hao · Shanghai Medical College of Fudan University2 papers (2023–2024) · 2 papers (2024–2025)Zhen Zhang · Suzhou Municipal Hospital2 papers (2022–2024)Yingying Zhang · Guangzhou University of Chinese Medicine2 papers (2024–2025)Conghua Xie · Wuhan University2 papers (2024–2025)Jiancheng Li · Yangtze University2 papers (2022–2025)Huanjun Yang · Shanghai Medical College of Fudan University2 papers (2022–2023)Honglei Luo · Nanjing Medical University2 papers (2024–2025)Yujin Xu · Sun Yat-sen University Cancer Center2 papers (2024–2025)Jiaying Deng · Shanghai Medical College of Fudan University2 papers (2023–2024)